RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/38933198/ below:

Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review

Review

. 2024 Feb 8;4(3):484-494. doi: 10.1016/j.fmre.2023.12.016. eCollection 2024 May. Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review Min Yang², Wei Xiong³, Quan Wang⁴, Bobo Zheng⁵, Yang Bai⁶, Kaiyong Zou¹, Jibin Li¹, Jiansong Ren¹, Wanqing Chen¹, Jingbo Zhai⁷, Jiang Li¹

Affiliations

¹ Office for Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
² Department of Comprehensive Intervention, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
³ Department of Gynecology Endocrine & Reproductive Center, National Clinical Research Center for Obstetric & Gynecologic Diseases Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing 100005, China.
⁴ Ambulatory Surgery Center of Xijing Hospital, Fourth Military Medical University, Xi'an 710068, China.
⁵ Department of General Surgery, Shaanxi Provincial People' s Hospital, Xi'an 710068, China.
⁶ College of Clinical Medicine, Capital Medical University, Beijing 100069, China.
⁷ School of Public Health, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.

PMID: 38933198
PMCID: PMC11197616
DOI: 10.1016/j.fmre.2023.12.016

Item in Clipboard

Review

Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review

Huilin Wang et al. Fundam Res. 2024.

. 2024 Feb 8;4(3):484-494. doi: 10.1016/j.fmre.2023.12.016. eCollection 2024 May. Authors Huilin Wang¹, Min Yang², Wei Xiong³, Quan Wang⁴, Bobo Zheng⁵, Yang Bai⁶, Kaiyong Zou¹, Jibin Li¹, Jiansong Ren¹, Wanqing Chen¹, Jingbo Zhai⁷, Jiang Li¹ Affiliations

¹ Office for Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
² Department of Comprehensive Intervention, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
³ Department of Gynecology Endocrine & Reproductive Center, National Clinical Research Center for Obstetric & Gynecologic Diseases Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing 100005, China.
⁴ Ambulatory Surgery Center of Xijing Hospital, Fourth Military Medical University, Xi'an 710068, China.
⁵ Department of General Surgery, Shaanxi Provincial People' s Hospital, Xi'an 710068, China.
⁶ College of Clinical Medicine, Capital Medical University, Beijing 100069, China.
⁷ School of Public Health, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.

PMID: 38933198
PMCID: PMC11197616
DOI: 10.1016/j.fmre.2023.12.016

Item in Clipboard

Abstract

The sudden onset of the coronavirus disease 2019 (COVID-19) in January 2020 has affected essential global health services. Cancer-screening services that can reduce cancer mortality are strongly affected. However, the specific role of COVID-19 in cancer screening is not fully understood. This study aimed to assess the efficiency of global cancer screening programs before and during the COVID-19 pandemic and to promote potential cancer-screening strategies for the next pandemic. Electronic searches in PubMed, Embase, and Web of Science, and manual searches were performed between January 1, 2020 and March 1, 2023. Cohort studies that reported the number of participants who underwent cancer screening before and during the COVID-19 pandemic were included. The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale. Differences in cancer-screening rates were estimated using the incidence rate ratio (IRR). Fifty-five cohort studies were included in this meta-analysis. The screening rates of colorectal cancer using invasive screening methods (Pooled IRR = 0.52, 95% CI: 0.42 to 0.65, p < 0.01), cervical cancer (Pooled IRR = 0.56, 95% CI: 0.47 to 0.67, p < 0.01), breast cancer (Pooled IRR = 0.57, 95% CI: 0.49 to 0.66, p < 0.01) and prostate cancer (Pooled IRR = 0.71, 95% CI: 0.56 to 0.90, p < 0.01) during the COVID-19 pandemic were significantly lower than those before the COVID-19 pandemic. The screening rates of lung cancer (Pooled IRR = 0.77, 95% CI: 0.58 to 1.03, p = 0.08) and colorectal cancer using noninvasive screening methods (Pooled IRR = 0.74, 95% CI: 0.50 to 1.09, p = 0.13) were reduced with no statistical differences. The subgroup analyses revealed that the reduction in cancer-screening rates varied across economies. Our results suggest that the COVID-19 pandemic has had a noteworthy impact on colorectal, cervical, breast, and prostate cancer screening. Developing innovative cancer-screening technologies is important to promote the efficiency of cancer-screening services in the post-COVID-19 era and prepare for the next pandemic.

Keywords: COVID-19 pandemic; Cancer screening; Cohort study; Incidence rate ratio; Meta-analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest in this work.

Figures
Fig. 1

PRISMA flow diagram of screening…

Fig. 1

PRISMA flow diagram of screening studies .

Fig. 1

PRISMA flow diagram of screening studies.

Fig. 2